Video Journal of Oncology (VJOncology)’s Post

Glioblastoma is the most aggressive malignant primary brain tumour with an average survival time of around 15-20 months. Research in Nature Communications identifies a molecular signature of network connectivity in glioblastoma, with the potential to inform novel biomarker and therapeutic development. Read the original article: https://lnkd.in/ezCWvnnt #cancerresearch #glioblastoma #biomarkerdiscovery

🧠🔬The #Tryptophan-#Kynurenine pathway surprises!🌱⚖️#Metabolites can be #Neuroprotective or #Neurotoxic based on context🤔See the latest review on KYN metabolism’s role in neurodegeneration, cancer & more! Preprints.org MDPI 📊💡 #Science #Metabolism

September is #GynecologicalCancer Awareness Month 📣 Check out this interview from #ASCO2024 | Emerging therapies in #gynecologiconcology at #ASCO2024 🎥 🇺🇸 Prof. Dr. Frederik Marmé, MD, PhD, Heidelberg University, discusses the results presented from studies investigating #gynecologicalcancers In #gynecologiconcology, dual #checkpointinhibitors, particularly the combination of #ipilimumab and #nivolumab, has shown promising results in #clearcellgynecologicalcancers, including #ovarian, #endometrial, and #cervicalcancers 🌟 A randomized study demonstrated that this combination therapy significantly improved response rates compared to single-agent strategies 💡 Another study focusing on #pembrolizumab and an anti-TIGIT #antibody in mismatch repair-deficient #endometrialcancer reported response rates in over half of the patients studied. The need for further investigation is highlighted, suggesting the exploration of their effects in combination with #chemotherapy Take a look 👉 https://lnkd.in/eexcmdpZ #GynaecologicalCancerAwarenessMonth #VJOncology #Oncologynews

🧠🔬The #Tryptophan-#Kynurenine pathway surprises!🌱⚖️#Metabolites can be #Neuroprotective or #Neurotoxic based on context🤔See the latest review on KYN metabolism’s role in neurodegeneration, cancer & more! Preprints.org MDPI 📊💡 #Science #Metabolism

Dysregulation of #GD2 expression and other gangliosides has implications for stratification and targeted therapeutic strategies in #neuroblastoma and other tumor entities, such as #osteosarcoma and #braintumors. However, the analysis of gangliosides is complex and requires dedicated technologies, that are currently not included in the commonly utilized high-throughput assays adopted in contexts such as molecular tumor boards. In this study, we present a method based on RNA-seq data that can discriminate between the different series of the ganglioside metabolism pathway. #childhoodcancer #pediatriccancer #CARTcells #Dinutuximab https://lnkd.in/e3tsDVDp

Not every patient responds to drugs in the same way 💊 . This may be due to differences in DNA. The structure of genes in DNA can make certain drugs work faster or slower. This is why geneticists are now creating a profile that can be used to determine exactly what patients' expected sensitivity is to certain medication. It will become available to our haematology patients this month. In cancer treatments such as stem cell therapy or CAR-T cell therapy, incorrect starting doses can have consequences. Haematologist 👩⚕️ Carolien Woolthuis expects a lot from the DNA profile: ‘It shows which dosage best suits the patient. That can make all the difference.' 👍 Geneticists Jackie Dekens and Lude Franke will investigate whether it can also be applied to patients with other conditions, such as cardiovascular disease. They will also investigate whether healthy individuals can also benefit. 'We want to know whether all the information is clear and whether participants also want to share it with their healthcare providers. And we would like to investigate whether it makes sense to make such a DNA profile of everyone.' Curious to find out more? ➡ https://lnkd.in/eTQpj--Q #haematology, #dna #lifelines

NEW from #ESMOGI2024 | Advancements in second-line #immunotherapy for #cholangiocarcinoma 🎥 🇩🇪 Do-Youn Oh, MD, PhD, Seoul National University College of Medicine, discusses second-line therapies and #immunotherapies for #cholangiocarcinoma Currently, the standard first-line treatment includes #nivolumab or #pembrolizumab with #chemotherapy If the disease progresses, second-line therapies such as #FOLFOX are used in the absence of #genetic alterations It is emphasized that the next step should be to develop new regimens that incorporate #immunecheckpointinhibitors in this line of treatment Learn more 👉 https://lnkd.in/ehntdDMQ #VJOncology #Oncologynews

A new epigenetic profile found in #MDS patients predicts treatment outcome with high accuracy, using a machine learning approach. A research British Journal of Haematology led by Dr. Manel Esteller's lab with colleagues from Institut Català d'Oncologia (ICO), Vall d'Hebron Institute of Oncology (VHIO) and Barcelona Supercomputing Center. Read the story: https://lnkd.in/ewUCKV7g ➡ The team compared the epigenetic profile of a cohort of patients after and before azacitidine treatment and found a specific epigenetic profile in those who responded to treatment. With that information, they trained a #MachineLearning algorithm that could correctly predict with high accuracy treatment outcome over a different patient cohort Among the findings, they found that hypomethylating agents help "awake" abnormaly silenced tumor supressor genes in the responder patients that could explain the therapeutic effect. Read the original paper here: https://lnkd.in/ev_96AFE

📍 Interpreting single-cell messages in normal and aberrant hematopoiesis Busarello et al. developed the Cell Marker Accordion, a user-friendly platform for the automatic annotation and biological interpretation of single-cell populations based on consistency weighted markers. Key points 📌 Validation on peripheral blood and bone marrow single-cell datasets 📌 Improved the accuracy in identifying cell types 📌 Identification of disease-critical cells, pathological processes and potential biomarkers 📌 Comprehensive characterization of acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome. ➡ More details: https://lnkd.in/e2AAyKMN #UniversityofTrento #spatialomics #spatialbiology #singlecellanalysis #singlecell

Advancements in Redox-Active Nanozymes! This study highlighted nanozymes' role in modulating cellular redox status, offering promising avenues for addressing oxidative-stress-related disorders. The latest findings on nanozymes' ability to emulate antioxidant enzymes in mammalian cells were discussed, showcasing their therapeutic potential in conditions like cancer, neurodegeneration, and cardiovascular diseases. These data shed light on the potential of nanozymes to revolutionize therapeutic interventions in oxidative-stress-mediated disorders, offering hope for improved treatment modalities in the future. 🌐 Read more: https://lnkd.in/dDGrxR3c #RedoxMedicine 2024 will introduce you to the latest redox innovations. Don't miss out! Join us this June in Paris to learn more! #RedoxMedicineSociety #RedoxMedicine #biomarkers #redoxbiology #redox #antioxidants #innovation #oxidativestress #Nanozymes #RedoxResearch #BiomedicalInnovation